18F-FACBC PET/MRI in Diagnostic Assessment and Neurosurgery of Gliomas
Tóm tắt
This pilot study aimed to evaluate the amino acid tracer 18F-FACBC with simultaneous PET/MRI in diagnostic assessment and neurosurgery of gliomas.
Eleven patients with suspected primary or recurrent low- or high-grade glioma received an 18F-FACBC PET/MRI examination before surgery. PET and MRI were used for diagnostic assessment, and for guiding tumor resection and histopathological tissue sampling. PET uptake, tumor-to-background ratios (TBRs), time-activity curves, as well as PET and MRI tumor volumes were evaluated. The sensitivities of lesion detection and to detect glioma tissue were calculated for PET, MRI, and combined PET/MRI with histopathology (biopsies for final diagnosis and additional image-localized biopsies) as reference.
Overall sensitivity for lesion detection was 54.5% (95% confidence interval [CI], 23.4–83.3) for PET, 45.5% (95% CI, 16.7–76.6) for contrast-enhanced MRI (MRICE), and 100% (95% CI, 71.5–100.0) for combined PET/MRI, with a significant difference between MRICE and combined PET/MRI (
Low- versus high-grade glioma differentiation may be possible with 18F-FACBC using TBR. 18F-FACBC PET/MRI outperformed MRICE in lesion detection and in detection of glioma tissue. More research is required to evaluate 18F-FACBC properties, especially in grade II and III tumors, and for different subtypes of gliomas.
Từ khóa
Tài liệu tham khảo
2015, CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008–2012, Neuro Oncol, 17, iv1, 10.1093/neuonc/nov189
2006, Epidemiology and molecular pathology of glioma, Nat Clin Pract Neurol, 2, 494, 10.1038/ncpneuro0289
2014, Changing incidence and improved survival of gliomas, Eur J Cancer, 50, 2309, 10.1016/j.ejca.2014.05.019
2016, The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary, Acta Neuropathol, 131, 803, 10.1007/s00401-016-1545-1
2006, EANM procedure guidelines for brain tumour imaging using labelled amino acid analogues, Eur J Nucl Med Mol Imaging, 33, 1374, 10.1007/s00259-006-0206-3
2014, Positron emission tomography–magnetic resonance imaging: technical review, Semin Roentgenol, 49, 242, 10.1053/j.ro.2014.10.001
2017, Neurologic applications of PET/MR imaging, Magn Reson Imaging Clin N Am, 25, 297, 10.1016/j.mric.2016.12.003
2017, Cardiac applications of PET/MR imaging, Magn Reson Imaging Clin N Am, 25, 325, 10.1016/j.mric.2016.12.007
2016, PET/MRI: emerging clinical applications in oncology, Acad Radiol, 23, 220
2016, Response assessment in Neuro-Oncology Working Group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas, Neuro Oncol, 18, 1199, 10.1093/neuonc/now058
2019, Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [(18)F]FDG: version 1.0, Eur J Nucl Med Mol Imaging, 46, 540, 10.1007/s00259-018-4207-9
2015, The sum of tumour-to-brain ratios improves the accuracy of diagnosing gliomas using 18F-FET PET, PLos One, 10, e0140917, 10.1371/journal.pone.0140917
2013, Diagnostic performance of 18F-FET PET in newly diagnosed cerebral lesions suggestive of glioma, J Nucl Med, 54, 229, 10.2967/jnumed.112.109603
2015, Dynamic 18F-FET PET in suspected WHO grade II gliomas defines distinct biological subgroups with different clinical courses, Int J Cancer, 136, 2132, 10.1002/ijc.29259
2017, Carbon-11 and fluorine-18 labeled amino acid tracers for positron emission tomography imaging of tumors, Front Chem, 5, 124
1999, Synthesis and evaluation of [18F]1-amino-3-fluorocyclobutane-1-carboxylic acid to image brain tumors, J Nucl Med, 40, 331
2011, Detection of recurrent prostate carcinoma with anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid PET/CT and 111In-capromab pendetide SPECT/CT, Radiology, 259, 852, 10.1148/radiol.11102023
2007, Initial experience with the radiotracer anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma, J Nucl Med, 48, 56
2013, Regional distribution and kinetics of [18F]fluciclovine (anti-[18F]FACBC), a tracer of amino acid transport, in subjects with primary prostate cancer, Eur J Nucl Med Mol Imaging, 40, 394, 10.1007/s00259-012-2291-9
2017, Diagnostic performance and safety of positron emission tomography using 18F-fluciclovine in patients with clinically suspected high- or low-grade gliomas: a multicenter phase IIb trial, Asia Ocean J Nucl Med Biol, 5, 10
2016, Phase IIa clinical study of [18F]fluciclovine: efficacy and safety of a new PET tracer for brain tumors, Ann Nucl Med, 30, 608, 10.1007/s12149-016-1102-y
2006, [18F]FACBC Imaging of recurrent gliomas: a comparison with [11C]methionine and MRI, J Nucl Med, 47
2016, 18F-fluciclovine (FACBC) PET/CT in residual or recurrent gliomas, J Nucl Med, 57, 1512
2017, Diagnosis of brain tumors using amino acid transport PET imaging with 18F-fluciclovine: a comparative study with l-methyl-11C-methionine PET imaging, Asia Ocean J Nucl Med Biol, 5, 85
2011, Synthesis, uptake mechanism characterization and biological evaluation of F-18 labeled fluoroalkyl phenylalanine analogs as potential PET imaging agents, Nucl Med Biol, 38, 53, 10.1016/j.nucmedbio.2010.07.005
2013, Role of O-(2-18F-fluoroethyl)-L-tyrosine PET as a diagnostic tool for detection of malignant progression in patients with low-grade glioma, J Nucl Med, 54, 2046, 10.2967/jnumed.113.123836
2012, MRI-suspected low-grade glioma: is there a need to perform dynamic FET PET?, Eur J Nucl Med Mol Imaging, 39, 1021, 10.1007/s00259-012-2109-9
2015, Prognostic significance of dynamic 18F-FET PET in newly diagnosed astrocytic high-grade glioma, J Nucl Med, 56, 9, 10.2967/jnumed.114.144675
2011, Molecular imaging of gliomas with PET: opportunities and limitations, Neuro Oncol, 13, 806, 10.1093/neuonc/nor054
2006, Analysis of 18F-FET PET for grading of recurrent gliomas: is evaluation of uptake kinetics superior to standard methods?, J Nucl Med, 47, 393
2013, Radiolabeled amino acids for oncologic imaging, J Nucl Med, 54, 1007, 10.2967/jnumed.112.113100
2015, Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials, Neuro Oncol, 17, 1188
2011, Intra-operative imaging with 3D ultrasound in neurosurgery, Acta Neurochir Suppl, 109, 181, 10.1007/978-3-211-99651-5_28
2017, Multimodal 18F-Fluciclovine PET/MRI and ultrasound-guided neurosurgery of an anaplastic oligodendroglioma, World Neurosurg, 108, 989.e1, 10.1016/j.wneu.2017.08.085
2015, Automatic deformable MR-ultrasound registration for image-guided neurosurgery, IEEE Trans Med Imaging, 34, 366, 10.1109/TMI.2014.2354352
2007, Prognostic value of O-(2-18F-fluoroethyl)-L-tyrosine PET and MRI in low-grade glioma, J Nucl Med, 48, 519, 10.2967/jnumed.106.037895
2004, Delineation of brain tumor extent with [11C]L-methionine positron emission tomography: local comparison with stereotactic histopathology, Clin Cancer Res, 10, 7163, 10.1158/1078-0432.CCR-04-0262
2013, Biopsy validation of 18F-DOPA PET and biodistribution in gliomas for neurosurgical planning and radiotherapy target delineation: results of a prospective pilot study, Neuro Oncol, 15, 1058, 10.1093/neuonc/not002
2005, O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas, Brain, 128, 678, 10.1093/brain/awh399
1999, Investigation of transport mechanism and uptake kinetics of O-(2-[18F]fluoroethyl)-L-tyrosine in vitro and in vivo, J Nucl Med, 40, 1367
2015, System L amino acid transporter LAT1 accumulates O-(2-fluoroethyl)-L-tyrosine (FET), Amino Acids, 47, 335, 10.1007/s00726-014-1863-3
2004, System l-amino acid transporters are differently expressed in rat astrocyte and C6 glioma cells, Neurosci Res, 50, 437, 10.1016/j.neures.2004.08.003
2014, Differences in transport mechanisms of trans-1-amino-3-[18F]fluorocyclobutanecarboxylic acid in inflammation, prostate cancer, and glioma cells: comparison with l-[methyl-11C]methionine and 2-deoxy-2-[18F]fluoro-d-glucose, Mol Imaging Biol, 16, 322, 10.1007/s11307-013-0693-0
2012, Transport mechanisms of trans-1-amino-3-fluoro[1-(14)C]cyclobutanecarboxylic acid in prostate cancer cells, Nucl Med Biol, 39, 109, 10.1016/j.nucmedbio.2011.06.008
2013, Kinetic analyses of trans-1-amino-3-[18F]fluorocyclobutanecarboxylic acid transport in Xenopus laevis oocytes expressing human ASCT2 and SNAT2, Nucl Med Biol, 40, 670, 10.1016/j.nucmedbio.2013.03.009
2005, Amino acid transporters ASCT2 and LAT1 in cancer: partners in crime?, Semin Cancer Biol, 15, 254, 10.1016/j.semcancer.2005.04.005
2008, l-type amino acid transporter 1 and CD98 expression in primary and metastatic sites of human neoplasms, Cancer Sci, 99, 2380, 10.1111/j.1349-7006.2008.00969.x
2011, Solute carrier transporters as targets for drug delivery and pharmacological intervention for chemotherapy, J Pharm Sci, 100, 3731, 10.1002/jps.22576
2004, Increased expression of a glutamine transporter SNAT3 is a marker of malignant gliomas, Neuroreport, 15, 575, 10.1097/00001756-200403220-00001
2016, Serial 18F-FET PET imaging of primarily 18F-FET-negative glioma: does it make sense?, J Nucl Med, 57, 1177, 10.2967/jnumed.115.171033
2016, A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas, Acta Neuropathol Commun, 4, 79, 10.1186/s40478-016-0351-2